Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AER002
- Development stage
- Phase 2
- Lead developer
- Aerium Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AER002 is a long-acting fully human anti-SARS-CoV-2 spike protein monoclonal antibody that blocks spike-ACE2 interactions, viral attachment and internalization. It is being developed by Aerium Therapeutics for the treatment of post-acute COVID-19 syndrome (Long COVID). The antibody has demonstrated potent neutralization against multiple SARS-CoV-2 variants including Alpha, Beta, Delta, and several Omicron subvariants, though it has reduced effectiveness against newer variants like BQ.1.1, XBB.1, and XBB.1.5. In clinical trials, it has shown an extended half-life of 97.5 days and good safety profile.
- Brand names
- AerolyticPulmolytic
- Other names
- bikuninrecombinant truncated SPINT2 protease inhibitorurinary trypsin inhibitor
02
Targets
Spike-ACE2 PPI (SARS-CoV-2 spike–ACE2 interface)
Beyond the preview
Go deeper on AER002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AER002.